Israeli cancer detection startup MetaSight is being acquired by Guardant Health in a deal worth up to $150 million.
The agreement includes an upfront payment of $59 million, with additional milestone-based payments that could raise the total value to $150 million.
MetaSight develops blood tests using liquid biopsy technology to detect cancer and other diseases at an early stage.
The company was founded by Prof. Tomer Shlomi of the Technion in collaboration with the aMoon fund through its Velocity program, which supports the launch of new startups. Dr. Yaron Daniely, former CEO of Yissum, Hebrew University’s technology transfer company, is a senior partner at aMoon, serves as MetaSight’s chairman, and has been actively involved with the company.
Guardant Health, founded in 2012, is a precision medicine company dedicated to extending cancer-free lives. Using advanced blood and tissue tests, real-world data, and AI analytics, Guardant provides critical insights to guide early detection, monitor recurrence, and support treatment decisions, improving outcomes across all stages of cancer care.
Meta Sight has raised approximately $20 million in two funding rounds to date, including $8 million in its most recent round with participation from the US-based ARC Fund.
Guardant Health’s acquisition of MetaSight highlights the increasing focus on technologies for early disease detection. Liquid biopsies provide a non-invasive way to identify cancer and other conditions, making them a crucial tool in modern medicine. Experts anticipate their importance will grow, enabling faster and more accurate diagnoses in the years ahead.
Read More – HUMAIN Acquires Significant Minority Stake in xAI Through $3 Billion Series E Investment
